ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
Treatment With Phosphodiesterase 5 Inhibitors and Long-Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long-term outcomes in patients with cardiovascular disease are not well understood.
objectiveWe studied the association between PDE5 inhibitor therapy and the incidence of adverse cardiovascular major adverse cardiovascular events (MACE) in patients undergoing coronary angiography and intervention.
methodsWe studied 4582 consecutive patients undergoing coronary angiography and intervention. The incidence of MACE at 1 year, defined as urgent revascularization, myocardial infarction, admission for heart failure or all-cause death, was considered the primary outcome.
resultsOf the 4582 patients, 562 (12.3%) had current prescriptions for PDE5 inhibitors before the procedure and 4020 (87.7%) did not. The incidence of MACE was 171 (30.4%) among patients of the PDE5 inhibitor group versus 1482 (36.9%) in the non-PDE5 inhibitor group (p = 0.003). In a propensity score-matched analysis of 1124 of patients, 171 (30.4%) patients in the PDE5i group and 175 (31.1%) patients in the non-PDE5i group had a MACE (p = 0.84). On multivariable analysis, the treatment with PDE5 inhibitors was not significantly associated with the risk of MACE (odds ratio [OR] = 0.99, 95% CI 0.93-1.06; p = 0.86).
conclusionIn this cohort of veterans undergoing coronary angiography/cardiac catheterization, chronic PDE5i therapy was not associated with an increased risk of MACE at 1 year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.